A patented, synthetic CBD to address pain and addiction

Supera-CBD is a synthetic, preclinical cannabidiol derivative that targets CB2 receptors.

POTENTIALLY MORE EFFECTIVE THAN CBD

Supera-CBD is non-toxic and approximately 7-8X more effective than plant-derived CBD in reducing MAO-A and MAO-B, which play a role in substance addiction, in a dose-dependent manner.

ROBUST PLATFORM

Supera-CBD is being developed to address anxiety, chronic pain, and seizures and is expected to begin human trials as a therapy for epilepsy, followed by chronic pain.

INHIBITS OPIOID RECEPTORS

Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based CBD. Opioid receptors are G protein-coupled receptors, widely expressed in the brain, spinal cord, peripheral neurons, and digestive tract.

Pre-clinical studies

Supera-CBD is a novel synthetic molecule with stark functional and structural similarity to cannabidiol (CBD).

In studies with scientific collaborators, Supera-CBD has demonstrated antidepressant and anti-anxiety effects with much higher potency and efficacy than plant-derived CBD.  CBD has broad therapeutic properties across a range of neuropsychiatric disorders, but without the psychoactive effects of THC.

Research

Academic presentations and resources

STRUCTURE OF Supera-CBD

Learn more about the structure of Supera-CBD

Download the resource

Supera-CBD: A NOVEL CBD DERIVED DRUG CANDIDATE

See the poster presented at the 3rd Annual Neuroimmunology Drug Development Conference

Download the poster presentation

Addressing an unmet need for pharmaceutical cannabinoids

Building on CBD’s enormous pre-existing market acceptance and the FDA’s declared receptiveness to moving forward in this space, Supera-CBD is positioned to become a prescription drug alternative to unregulated CBD.

View TNF Pharmaceuticals Thought Leadership and News
  • This field is for validation purposes and should be left unchanged.